New pathogenic features in sleep apnea-hypopnea syndrome (SAHS);Nuevos aspectos patogénicos en el síndrome de apneas e hipopneas durante el sueño (SAHS)

Archivos de Bronconeumologia

Volumn 43, Issue SUPPL.2, 2007, Pages 40-47

  Nácher, María ^a   Serrano Mollar, Anna ^b   Montserrat, Josep Maria ^a,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Cellular mediators; Mechanisms; Sleep apnea; Vascular disease

Indexed keywords

ANTIOXIDANT; FREE RADICAL; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; CARDIOVASCULAR EFFECT; CORONARY ARTERY ATHEROSCLEROSIS; CRANIOFACIAL MORPHOLOGY; DISEASE ASSOCIATION; GENETIC DISORDER; HEREDITY; HUMAN; HYPOXIA; INFLAMMATION; LUNG CAPACITY; LUNG VENTILATION; OBESITY; OXIDATIVE STRESS; PHENOTYPE; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; SYMPTOM; UPPER RESPIRATORY TRACT OBSTRUCTION;

EID: 34547681471     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13097000     Document Type: Review

References (44)

1. Abbas AK. Cellular and molecular inmunology. Philadelphia: Sanders; 2003.
2. Alberts B. Molecular biology of the cell. New York: Garland Science; 2002.
3. Paulsen FP, Steven P, Tsokos M, Jungmann K, Muller A, Verse T. Upper airway epithelial structural changes in obstructive sleep-disordered breathing. Am J Respir Crit Care Med. 2002;166:501-9.
4. Rubinstein I. Nasal inflammation in patients with obstructive sleep apnea. Laryngoscope. 1995;105:175-7.
5. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest. 2002;122:1162-7.
6. Salerno FG, Carpagnano E, Guido P, Bonsignore MR, Roberti A, Aliani M. Airway inflammation in patients affected by obstructive sleep apnea syndrome. Respir Med. 2004;98:25-8.
7. Calero G, Serrano-Mollar A, Farré R, Closa D, Navajas D, Montserrat JM. Lung inflammation in a rat model of obstructive sleep apnea. Role of strenuous breathing. Am J Respir Crit Care Med. 2003;169:A432.
8. Woodson BT, Garancis JC, Toohill RJ. Histopathologic changes in snoring and obstructive sleep apnea syndrome. Laryngoscope. 1991;101:1318-22.
9. Sekosan M, Zakkar M, Wenig BL, Olopade CO, Rubinstein I. Inflammation in the uvula mucosa of patients with obstructive sleep apnea. Laryngoscope. 1996;106:1018-20.
10. Bradley TD, Floras JS. Sleep apnea and heart failure. Part II: central sleep apnea. Circulation. 2003;107:1822-6.
11. Tkacova R, Rankin F, Fitzgerald FS, Floras JS, Bradley TD. Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation. 1998;98:2269-75.
12. Fletcher EC. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol. 2000;119:189-97.
13. Barceló A, Barbé F. Estrés oxidativo y síndrome de apneas-hipopneas del sueño. Arch Bronconeumol. 2005;41:393-9.
14. Lavie L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev. 2003;7:35-51.
15. Montserrat J, Hernández L, Nacher M, Barbé F. Nuevos aspectos patogénicos en el síndrome de apneas e hipopneas durante el sueño (SAHS) Arch Bronconeumol. 2004;40 Supl 6:27-34.
16. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J. 2003;146:218-26.
17. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part III: biomarkers of oxidative stress and angiogenic growth factors. Circulation. 2006;113:e289-e92.
18. Maulik N, Das DK. Redox signaling in vascular angiogenesis. Free Radic Biol Med. 2002;33:1047-60.
19. Baldwin CM, Bootzin RR, Schwenke DC, Quan SF. Antioxidant nutrient intake and supplements as potential moderators of cognitive decline and cardiovascular disease in obstructive sleep apnea. Sleep Med Rev. 2005;9:459-76.
20. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 1999;45:7-17.
21. Kopp Bk, Ghosh S. NF-β and Rel proteins in innate immunity. Adv Immunol. 1995;58:1-27.
22. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, et al. Signal-induced site-specific phosphorylation targets IκBα to the ubiqitin-proteasome pathway. Genes Dev. 1995;9:1586-97.
23. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax. 1998;53:601-12.
24. Ritchter C, Cogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, et al. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta. 1995;127:67-74.
25. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterisation of an IκB kinase. Cell. 1997;338:548-54.
26. Blackwell TS, Christman JW, The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997;17:3-9.
27. Piacentini L, Karliner JS. Altered gene expression during hypoxia and reoxygenation of the heart. Pharmacol Ther. 1999;83:21-37.
28. Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol. 2003;94:179-84.
29. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med. 2002;165:934-9.
30. Ohga E, Nagase T, Tomita T, Teramoto S, Matsuse T, Katayama H, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol. 1999;87:10-4.
31. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun. 2006; 343:591-6.
32. Semenza GL. Oxygen-regulated transcription factors and their role in pulmonary disease. Respir Res. 2000;1:159-62.
33. Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem. 2006;387:1337-46.
34. Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med. 2002;165:67-70.
35. Svatikova A, Shamsuzzaman AS, Wolk R, Phillips BG, Olson LJ, Somers VK. Plasma brain natriuretic peptide in obstructive sleep apnea. Am J Cardiol. 2004;94:529-32.
36. Brzecka A. Brain preconditioning and obstructive sleep apnea syndrome. Acta Neurobiol Exp. 2005;65:213-20.
37. Jordan W, Reinbacher A, Cohrs S, Grunewald RW, Mayer G, Ruther E, et al. Obstructive sleep apnea: plasma endothelin-1 precursor but not endothelin-1 levels are elevated and decline with nasal continuous positive airway pressure. Peptides. 2005;26:1654-60.
38. Ikeda E. Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int. 2005;55:603-10.
39. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-9.
40. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-H1002.
41. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.
42. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S-60S
43. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
44. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26.